세계의 나노 면역요법 전달 시장 예측(-2032년) : 나노캐리어 유형별, 표적화 메커니즘별, 치료 모달리티별, 투여 경로별, 최종사용자별, 지역별 분석

According to Stratistics MRC, the Global Nano-Immunotherapy Delivery Market is accounted for $3.1 billion in 2025 and is expected to reach $3.8 billion by 2032 growing at a CAGR of 3% during the forecast period. Nano-Immunotherapy Delivery systems use nanoscale carriers to transport immune-modulating agents directly to targeted cells or tissues. These carriers, often engineered nanoparticles, enhance drug stability, precision targeting, and controlled release. By focusing therapeutic payloads on specific immune pathways, they improve efficacy while minimizing side effects. Applications include cancer treatment, autoimmune regulation, and vaccine enhancement. Nano-immunotherapy delivery represents a fusion of nanotechnology and immunology, enabling highly personalized and efficient interventions in complex disease management.

According to the Cancer Research Institute, lipid nanoparticle delivery systems, proven by their success in mRNA vaccines, are now the leading platform for targeted solid-tumor immunotherapy, with over 120 clinical trials currently underway.

Market Dynamics:

Driver:

Rising demand for targeted immunomodulation

The market is driven by increasing demand for targeted immunomodulation, enabling precise control of immune responses in cancer, autoimmune, and infectious diseases. Nano-delivery systems allow localized action, reducing systemic side effects and improving therapeutic efficacy. Advances in nanocarrier design, including lipid nanoparticles and polymeric systems, support tailored delivery of cytokines, antibodies, and vaccines. This demand is reinforced by the global shift toward precision medicine, positioning nano-immunotherapy as a critical tool for next-generation healthcare solutions.

Restraint:

Complexity of nanoparticle biocompatibility

A major restraint is the complexity of ensuring nanoparticle biocompatibility. Nano-carriers must interact safely with biological systems, avoiding immune rejection, toxicity, or unintended biodistribution. Achieving stability in vivo while maintaining therapeutic efficacy requires advanced engineering and extensive validation. Regulatory hurdles further complicate commercialization, as long-term safety data is limited. These challenges increase development costs and slow clinical adoption, making biocompatibility a critical barrier to scaling nano-immunotherapy delivery across diverse therapeutic applications.

Opportunity:

Advances in immune nanocarrier platforms

Significant opportunity lies in advances in immune nanocarrier platforms, which enable multifunctional delivery of drugs, vaccines, and genetic material. Innovations in hybrid nanocarriers, exosome-inspired systems, and stimuli-responsive designs are expanding therapeutic potential. These platforms can simultaneously target immune cells, modulate microenvironments, and enhance intracellular trafficking. As research accelerates, immune nanocarriers are poised to revolutionize treatment strategies, offering safer, more effective, and personalized solutions for oncology, infectious diseases, and autoimmune disorders.

Threat:

Safety concerns around long-term toxicity

The market faces threats from safety concerns related to long-term nanoparticle toxicity. Accumulation in organs, unforeseen immune reactions, and chronic exposure risks raise caution among regulators and clinicians. Limited longitudinal data makes it difficult to fully assess safety profiles, slowing approvals and adoption. Public perception of nanomedicine safety also influences market growth. Addressing these concerns through rigorous testing, transparent reporting, and advanced biocompatible designs is essential to mitigate risks and sustain confidence in nano-immunotherapy delivery.

Covid-19 Impact:

Covid-19 accelerated adoption of nano-immunotherapy delivery, particularly lipid nanoparticles used in mRNA vaccines. The pandemic validated nanocarrier platforms as scalable, safe, and effective for rapid immunization. This success boosted investment in nano-delivery technologies for broader immunotherapy applications. Post-pandemic, the market benefits from heightened awareness of immune modulation and preparedness for future outbreaks. The crisis ultimately strengthened confidence in nanomedicine, positioning nano-immunotherapy delivery as a cornerstone of modern healthcare innovation.

The lipid nanoparticles (LNPs) segment is expected to be the largest during the forecast period

The lipid nanoparticles (LNPs) segment is expected to account for the largest market share during the forecast period, driven by their proven success in vaccine delivery and therapeutic applications. LNPs offer biocompatibility, scalability, and efficient encapsulation of nucleic acids and proteins. Their widespread use in Covid-19 vaccines demonstrated reliability, accelerating adoption in oncology and autoimmune therapies. As demand for safe, versatile nanocarriers grows, LNPs remain the dominant choice, securing their position as the largest contributor to market share during the forecast period.

The active ligand-mediated targeting segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the active ligand-mediated targeting segment is predicted to witness the highest growth rate, propelled by its precision in directing nanocarriers to specific immune cells or tissues. By attaching ligands such as antibodies, peptides, or aptamers, these systems enhance therapeutic efficacy and reduce off-target effects. Advances in ligand engineering and receptor profiling are expanding applications in cancer immunotherapy and autoimmune disease management. This high specificity positions ligand-mediated targeting as the fastest-growing segment in nano-immunotherapy delivery.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, attributed to expanding healthcare infrastructure, rising prevalence of chronic diseases, and strong government support for biotechnology. Countries like China, Japan, and India are investing heavily in nanomedicine research and clinical trials. Cost-effective manufacturing and growing patient populations further reinforce regional dominance. With increasing adoption of advanced therapies, Asia Pacific remains the leading hub for nano-immunotherapy delivery, driving large-scale commercialization and market leadership.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR supported by advanced R&D, strong regulatory frameworks, and early adoption of nanomedicine. The U.S. leads with robust investment in immunotherapy, clinical trials, and biotech startups. High prevalence of cancer and autoimmune disorders accelerates demand for precision therapies. Favorable reimbursement policies and integration with healthcare systems further strengthen growth. With innovation and infrastructure, North America is positioned as the fastest-growing region in the nano-immunotherapy delivery market.

Key players in the market

Some of the key players in Nano-Immunotherapy Delivery Market include Moderna, BioNTech, Pfizer, AstraZeneca, Novartis, Sanofi, Johnson & Johnson, Gilead Sciences, Roche, Merck, Bayer, Takeda, BD Biosciences, Thermo Fisher Scientific, Danaher, Catalent, Evonik Health Care, and Precision NanoSystems.

Key Developments:

In November 2025, Moderna unveiled its next-generation lipid nanoparticle (LNP) delivery platform for oncology immunotherapies. The innovation enables precise targeting of tumor microenvironments, offering rapid immune activation with improved safety profiles.

In October 2025, BioNTech launched its AI-enhanced nano-carrier system designed to optimize mRNA immunotherapy delivery. The system integrates adaptive algorithms to personalize dosing and improve therapeutic outcomes in cancer and autoimmune disorders.

In September 2025, Pfizer announced the rollout of its scalable nano-immunotherapy manufacturing suite to support global clinical trials. The facility focuses on advanced encapsulation technologies, ensuring consistent quality and faster translation from lab to patient care.

Nanocarrier Types Covered:

• Lipid Nanoparticles (LNPs)
• Polymeric Nanoparticles
• Protein & Peptide-Based Nanocarriers
• Inorganic Nanoparticles (Gold, Silica)
• Exosome & Vesicle-Based Delivery
• Hybrid Multifunctional Nanocarriers

Targeting Mechanisms Covered:

• Passive Tumor Targeting (EPR Effect)
• Active Ligand-Mediated Targeting
• Stimuli-Responsive Release Systems
• Cell-Directed Delivery (APCs/T Cells)
• Intracellular Trafficking Enhancers
• Immune Microenvironment Modulators

Therapeutic Modalities Covered:

• Cancer Immunotherapy Delivery
• Vaccine & Adjuvant Delivery
• Autoimmune Modulation Therapies
• Adoptive Cell Therapy Support Systems
• Gene-Editing & RNA-based Immunotherapies
• Combination Nanotherapy Platforms

Administration Routes Covered:

• Intravenous Delivery Systems
• Intratumoral & Localized Delivery
• Inhalation & Pulmonary Delivery
• Oral & Mucosal Nanodelivery
• Transdermal & Microneedle Platforms
• Implantable Depot Systems

End Users Covered:

• Pharmaceutical & Biotech Companies
• Academic & Clinical Research Centers
• Hospitals & Oncology Centers
• Contract Development & Manufacturing Organizations (CDMOs)
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Nano-Immunotherapy Delivery Market, By Nanocarrier Type

• 5.1 Introduction
• 5.2 Lipid Nanoparticles (LNPs)
• 5.3 Polymeric Nanoparticles
• 5.4 Protein & Peptide-Based Nanocarriers
• 5.5 Inorganic Nanoparticles (Gold, Silica)
• 5.6 Exosome & Vesicle-Based Delivery
• 5.7 Hybrid Multifunctional Nanocarriers

6 Global Nano-Immunotherapy Delivery Market, By Targeting Mechanism

• 6.1 Introduction
• 6.2 Passive Tumor Targeting (EPR Effect)
• 6.3 Active Ligand-Mediated Targeting
• 6.4 Stimuli-Responsive Release Systems
• 6.5 Cell-Directed Delivery (APCs/T Cells)
• 6.6 Intracellular Trafficking Enhancers
• 6.7 Immune Microenvironment Modulators

7 Global Nano-Immunotherapy Delivery Market, By Therapeutic Modality

• 7.1 Introduction
• 7.2 Cancer Immunotherapy Delivery
• 7.3 Vaccine & Adjuvant Delivery
• 7.4 Autoimmune Modulation Therapies
• 7.5 Adoptive Cell Therapy Support Systems
• 7.6 Gene-Editing & RNA-based Immunotherapies
• 7.7 Combination Nanotherapy Platforms

8 Global Nano-Immunotherapy Delivery Market, By Administration Route

• 8.1 Introduction
• 8.2 Intravenous Delivery Systems
• 8.3 Intratumoral & Localized Delivery
• 8.4 Inhalation & Pulmonary Delivery
• 8.5 Oral & Mucosal Nanodelivery
• 8.6 Transdermal & Microneedle Platforms
• 8.7 Implantable Depot Systems

9 Global Nano-Immunotherapy Delivery Market, By End User

• 9.1 Introduction
• 9.2 Pharmaceutical & Biotech Companies
• 9.3 Academic & Clinical Research Centers
• 9.4 Hospitals & Oncology Centers
• 9.5 Contract Development & Manufacturing Organizations (CDMOs)
• 9.6 Other End Users

10 Global Nano-Immunotherapy Delivery Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Moderna
• 12.2 BioNTech
• 12.3 Pfizer
• 12.4 AstraZeneca
• 12.5 Novartis
• 12.6 Sanofi
• 12.7 Johnson & Johnson
• 12.8 Gilead Sciences
• 12.9 Roche
• 12.10 Merck
• 12.11 Bayer
• 12.12 Takeda
• 12.13 BD Biosciences
• 12.14 Thermo Fisher Scientific
• 12.15 Danaher
• 12.16 Catalent
• 12.17 Evonik Health Care
• 12.18 Precision NanoSystems